Ebneter, Andreas
Michels, Stephan
Pruente, Christian
Imesch, Pascal
Eilenberger, Felix
Oesch, Susanne
Thomet-Hunziker, Isabelle P.
Hatz, Katja
Article History
Received: 25 June 2020
Accepted: 1 October 2020
First Online: 20 November 2020
Competing interests
: A. Ebneter has received financial support from Bayer AG, Allergan AG, Novartis AG, and research support from Plexxikon Inc. The respective reimbursement was received by the research foundation at Inselgruppe AG Bern, Switzerland. S. Michels received compensation for consultancy work from Bayer, Novartis, Allergan, Roche, and Braem AG. C. Pruente received research support from Bayer, Novartis and Roche. He served as consultant for Alcon, Allergan, Bayer, Novartis, Roche and Kinarus. P. Imesch received research support from Bayer and Novartis, and received compensation for advisory board meetings from Bayer, Novartis and Allergan. S. Oesch is an employee of Bayer (Schweiz) AG and a stockholder of Bayer AG. F. Eilenberger was an employee of the CRO Alcedis GmbH. Alcedis was contracted for statistical analysis by Bayer (Schweiz) AG. ITH was an employee of Bayer (Schweiz) AG. K. Hatz received research support from Bayer, Novartis, and Allergan, received compensation for advisory board meetings from Bayer, Novartis, Allergan, and Roche, and worked as consultant for Kinarus AG. The study was initiated and funded by Bayer (Schweiz) AG, Zürich, Switzerland. The authors have no proprietary interest on the content described in the article.